← Amneal Pharmaceuticals, Inc. Class A Common Stock overview

Amneal Pharmaceuticals, Inc. Class A Common Stock vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

Q3 202615 Jul – 4 Sep 2026

▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.
This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.
Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.
The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.
FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.
New regulatory approval directly enables additional sales and market share in an existing product category.
Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.
This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

August 202615 Jul – 4 Sep 2026

▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.
This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.
Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.
The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.
FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.
New regulatory approval directly enables additional sales and market share in an existing product category.
Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.
This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

Latest15 Jul – 4 Sep 2026

▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.
This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.
Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.
The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.
FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.
New regulatory approval directly enables additional sales and market share in an existing product category.
Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.
This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.